FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2045486039> ?p ?o ?g. }

• W2045486039 endingPage "853" @default.
• W2045486039 startingPage "847" @default.
• W2045486039 abstract "Rationale: Gefitinib is effective in treating patients with non–small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. Deletions in exon 19 and L858R in exon 21 are the best-documented EGFR mutations that are associated with effective gefitinib responsiveness.Objectives: To clarify the influence of gefitinib timing, we conducted a study to compare the outcomes of different lines of gefitinib treatment in patients with exon 19 deletions or L858R.Methods: We surveyed the clinical data and mutational studies of patients with NSCLC with EGFR mutations in the National Taiwan University Hospital (Taipei, Taiwan).Measurements and Main Results: Three hundred and twenty-eight patients, who received gefitinib for stage IIIb or IV NSCLC, were adequately sequenced for EGFR mutations; 192 patients had mutant EGFR, including 77 patients with exon 19 deletions and 75 patients with L858R. The 152 patients with exon 19 deletions or L858R and who were receiving gefitinib were classified into a chemonaive group (91 patients) or a chemotherapy-treated group (61 patients). Chemonaive status before gefitinib and female sex were associated with clinical response to gefitinib (P = 0.006 and 0.053, respectively). Neither overall survival after the start of antitumor therapy nor progression-free survival after gefitinib therapy was significantly different between these two groups (P = 0.207 and 0.804, respectively). Clinical response to gefitinib was the only factor associated with better overall survival (P = 0.001).Conclusions: This study suggests that gefitinib is effective in patients with EGFR mutations. The gefitinib response rate in chemonaive patients is higher than in chemotherapy-treated patients; however, there is no difference in overall survival." @default.
• W2045486039 created "2016-06-24" @default.
• W2045486039 creator A5012845951 @default.
• W2045486039 creator A5013389671 @default.
• W2045486039 creator A5029206619 @default.
• W2045486039 creator A5036843957 @default.
• W2045486039 creator A5043010373 @default.
• W2045486039 creator A5046481278 @default.
• W2045486039 creator A5048965137 @default.
• W2045486039 creator A5051085368 @default.
• W2045486039 creator A5061148129 @default.
• W2045486039 creator A5067347318 @default.
• W2045486039 creator A5084204217 @default.
• W2045486039 date "2008-10-15" @default.
• W2045486039 modified "2023-09-27" @default.
• W2045486039 title "First- or Second-line Therapy with Gefitinib Produces Equal Survival in Non–Small Cell Lung Cancer" @default.
• W2045486039 cites W1582187753 @default.
• W2045486039 cites W1931438814 @default.
• W2045486039 cites W1975276584 @default.
• W2045486039 cites W1982397643 @default.
• W2045486039 cites W2009481811 @default.
• W2045486039 cites W2020830322 @default.
• W2045486039 cites W2030864655 @default.
• W2045486039 cites W2030883899 @default.
• W2045486039 cites W2041738335 @default.
• W2045486039 cites W2043696829 @default.
• W2045486039 cites W2048538776 @default.
• W2045486039 cites W2048733384 @default.
• W2045486039 cites W2048790445 @default.
• W2045486039 cites W2051786446 @default.
• W2045486039 cites W2080847394 @default.
• W2045486039 cites W2093922887 @default.
• W2045486039 cites W2106297623 @default.
• W2045486039 cites W2114642822 @default.
• W2045486039 cites W2119831956 @default.
• W2045486039 cites W2120718661 @default.
• W2045486039 cites W2123206362 @default.
• W2045486039 cites W2125195105 @default.
• W2045486039 cites W2130254323 @default.
• W2045486039 cites W2130652363 @default.
• W2045486039 cites W2134667653 @default.
• W2045486039 cites W2135619328 @default.
• W2045486039 cites W2139248078 @default.
• W2045486039 cites W2140775102 @default.
• W2045486039 cites W2143171062 @default.
• W2045486039 cites W2143859186 @default.
• W2045486039 cites W2145230626 @default.
• W2045486039 cites W2146404049 @default.
• W2045486039 cites W2147703884 @default.
• W2045486039 cites W2148174696 @default.
• W2045486039 cites W2153477391 @default.
• W2045486039 cites W2161821474 @default.
• W2045486039 cites W2166399931 @default.
• W2045486039 cites W4251219890 @default.
• W2045486039 cites W4251385152 @default.
• W2045486039 doi "https://doi.org/10.1164/rccm.200803-389oc" @default.
• W2045486039 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18583573" @default.
• W2045486039 hasPublicationYear "2008" @default.
• W2045486039 type Work @default.
• W2045486039 sameAs 2045486039 @default.
• W2045486039 citedByCount "64" @default.
• W2045486039 countsByYear W20454860392012 @default.
• W2045486039 countsByYear W20454860392013 @default.
• W2045486039 countsByYear W20454860392014 @default.
• W2045486039 countsByYear W20454860392015 @default.
• W2045486039 countsByYear W20454860392016 @default.
• W2045486039 countsByYear W20454860392017 @default.
• W2045486039 countsByYear W20454860392019 @default.
• W2045486039 countsByYear W20454860392021 @default.
• W2045486039 countsByYear W20454860392022 @default.
• W2045486039 countsByYear W20454860392023 @default.
• W2045486039 crossrefType "journal-article" @default.
• W2045486039 hasAuthorship W2045486039A5012845951 @default.
• W2045486039 hasAuthorship W2045486039A5013389671 @default.
• W2045486039 hasAuthorship W2045486039A5029206619 @default.
• W2045486039 hasAuthorship W2045486039A5036843957 @default.
• W2045486039 hasAuthorship W2045486039A5043010373 @default.
• W2045486039 hasAuthorship W2045486039A5046481278 @default.
• W2045486039 hasAuthorship W2045486039A5048965137 @default.
• W2045486039 hasAuthorship W2045486039A5051085368 @default.
• W2045486039 hasAuthorship W2045486039A5061148129 @default.
• W2045486039 hasAuthorship W2045486039A5067347318 @default.
• W2045486039 hasAuthorship W2045486039A5084204217 @default.
• W2045486039 hasConcept C104317684 @default.
• W2045486039 hasConcept C121608353 @default.
• W2045486039 hasConcept C126322002 @default.
• W2045486039 hasConcept C143998085 @default.
• W2045486039 hasConcept C2776256026 @default.
• W2045486039 hasConcept C2779438470 @default.
• W2045486039 hasConcept C2780580887 @default.
• W2045486039 hasConcept C36823959 @default.
• W2045486039 hasConcept C54355233 @default.
• W2045486039 hasConcept C71924100 @default.
• W2045486039 hasConcept C86803240 @default.
• W2045486039 hasConceptScore W2045486039C104317684 @default.
• W2045486039 hasConceptScore W2045486039C121608353 @default.
• W2045486039 hasConceptScore W2045486039C126322002 @default.
• W2045486039 hasConceptScore W2045486039C143998085 @default.

• next